Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are tested for treatment decisions SECAUCUS, N.J. and BALTIMORE, May 31, 2024 /PRNewswire/ -- A blood test could help reduce costs for health plans by reliably identifying patients who might be able to safely forgo chemotherapy after surgery for stage II colorectal cancer, according to a study published today in J ...

Quest Diagnostics Q1 Earnings Surpass, Margins Crash Quest Diagnostics Incorporated's first-quarter 2024 adjusted earnings per share of $2.04 beat the Zacks Consensus Estimate by 9.7%. However, the metric came in line with the year-ago adjusted figure. Certain one-time expenses, like the ones related to amortization expenses, certain restructuring and integration charges, other expenses and excess tax benefits associated with stock-based compensations, were excluded from the quarter's adjusted figures. GAAP ...

SECAUCUS, N.J., May 16, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that its Board of Directors has elected Robert (Rob) B. Carter, a seasoned technology executive, to serve as a director. Including Mr. Carter, the company's Board has 10 members. Rob CarterRob Carter Mr. Carter, 64, is Executive Vice President and Chief Information Officer at FedEx Corporation, where he is responsible for setting the technology direction of the F ...

SECAUCUS, N.J., May 15, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on July 22, 2024 to shareholders of record of Quest Diagnostics common stock on July 8, 2024. SOURCE Quest Diagnostics About Quest Diagnostics Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from ...

Overall Drug Positivity Holds Steady at Historically High Rates while Marijuana Positivity Continued Upward Climb in the General U.S. Workforce Marijuana Positivity in the General U.S. Workforce Escalated in States That Have Legalized Recreational Marijuana as well as in Professional Office-Based Industries SECAUCUS, N.J., May 15, 2024 /PRNewswire/ -- The percentage of employees in the general U.S. workforce whose drug test showed signs of tampering increased by more than six-fold in 2023 versus the prior y ...

SECAUCUS, N.J., May 7, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas on Wednesday, May 29, 2024, at 10:20 a.m. Eastern Time. The fireside chat and Q&A session will be webcast live during the conf ...

Quest Diagnostics (DGX) recently announced a strategic collaboration with PathAI, a global leader in artificial intelligence-powered pathology technology, aimed at revolutionizing cancer and disease diagnosis. This partnership marks a significant step toward accelerated adoption of AI and digital pathology in Quest Diagnostics’ diagnostic services, promising enhanced quality, speed and efficiency in healthcare.Transformative Acquisition of PathAI Diagnostics AssetsUnder this definitive agreement, Quest Diag ...

SECAUCUS, N.J., May 6, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced today that Murali Balakumar, a veteran information technology healthcare business leader, has been named Senior Vice President and Chief Information and Digital Officer (CIDO).Mr. Balakumar, based at the company's headquarters in Secaucus, N.J., is responsible for leading information technology, data informatics and digital solutions for Quest Diagnostics. Murali Bal ...

Quest Diagnostics (DGX) recently announced a multi-faceted collaboration with PathAI to accelerate the adoption of digital and AI pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases. Under a definitive agreement, the company will acquire select assets of PathAI Diagnostics, the business of PathAI that provides anatomic and digital pathology laboratory services.The latest development builds on Quest Diagnostics’ leadership in oncology and subspecialized path ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-12215 Quest Diagnostics Incorporated Delaware 16-1387862 500 Plaza Drive (State of Incorporation) (I.R.S. Employ ...